Napigen Overview
- Year Founded
-
2016
- Status
-
Private
- Employees
-
15
- Latest Deal Type
-
Series A
- (Cancelled)
- Investors
-
13
Napigen General Information
Description
Operator of a biotechnology company intended to address novel genome engineering of various organisms, such as plants, microbes, and animals. The company's technology targets two special cellular components known as organelles that harbor their DNA, named mitochondria and chloroplasts, which are important to create energy for cells to grow, enabling clients to harness the potential of organelles to make our society a convenient place to live.
Contact Information
Website
www.napigen.comCorporate Office
- 200 Powder Mill Road
- DISI-E500
- Wilmington, DE 19803
- United States
Corporate Office
- 200 Powder Mill Road
- DISI-E500
- Wilmington, DE 19803
- United States
Napigen Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 13. Later Stage VC (Series A) | 11-Mar-2024 | Cancelled | Generating Revenue | |||
| 12. Accelerator/Incubator | Completed | Generating Revenue | ||||
| 11. Later Stage VC | 12-Jul-2022 | Completed | Generating Revenue | |||
| 10. Grant | 01-Jun-2022 | Completed | Generating Revenue | |||
| 9. Later Stage VC | 08-Nov-2021 | Completed | Generating Revenue | |||
| 8. Grant | 31-Dec-2020 | Completed | Generating Revenue | |||
| 7. Grant | 01-Sep-2020 | Completed | Generating Revenue | |||
| 6. Early Stage VC | 12-Nov-2019 | Completed | Generating Revenue | |||
| 5. Early Stage VC | 25-Oct-2019 | $1M | $1.6M | Completed | Generating Revenue | |
| 4. Grant | 18-Sep-2019 | $100K | $600K | Completed | Generating Revenue |
VC Exit Predictor
See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.
Napigen Patents
Napigen Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| US-20260286374-A1 | Methods and compositions for genome editing in plants | Pending | 13-Jan-2025 | ||
| WO-2026151941-A2 | Methods and compositions for genome editing in plants | Pending | 13-Jan-2025 | ||
| WO-2026151941-A3 | Methods and compositions for genome editing in plants | Pending | 13-Jan-2025 | ||
| AU-2024230907-A1 | Herbicide-resistant genes for mitochondrial transformation | Pending | 09-Mar-2023 | ||
| EP-4677099-A2 | Herbicide-resistant genes for mitochondrial transformation | Pending | 09-Mar-2023 | C12N15/8275 |
Napigen Signals
Napigen Investors (13)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| RA Capital Management | Asset Manager | Minority | ||
| The Grantham Foundation | Limited Partner | Minority | ||
| Thiel Foundation | Not-For-Profit Venture Capital | Minority | ||
| United States Department of Agriculture | Government | |||
| Angel (individual) | Minority |
Napigen FAQs
-
When was Napigen founded?
Napigen was founded in 2016.
-
Where is Napigen headquartered?
Napigen is headquartered in Wilmington, DE.
-
What is the size of Napigen?
Napigen has 15 total employees.
-
What industry is Napigen in?
Napigen’s primary industry is Biotechnology.
-
Is Napigen a private or public company?
Napigen is a Private company.
-
What is Napigen’s current revenue?
The current revenue for Napigen is .
-
How much funding has Napigen raised over time?
Napigen has raised $9.6M.
-
Who are Napigen’s investors?
RA Capital Management, The Grantham Foundation, Thiel Foundation, United States Department of Agriculture, and are 5 of 13 investors who have invested in Napigen.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process